Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | HCK | P08631 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.42 |
| ▸ | PRKDC | P78527 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751204 | 0.91 | USP14 (0.38) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL3050311 | 0.84 | PIK3CD (0.38) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL3043931 | 0.82 | FAAH (0.39) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1057433 | 0.81 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL12043978 | 0.81 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL29658586 | 0.81 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL3657760 | 0.81 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16756072 | 0.80 | NR1H2 (0.52) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1058348 | 0.80 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL10819613 | 0.80 | PIK3CD (0.44) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0894235-B1 | FIRING MIXTURES | DYNAMIT NOBEL AG (DE) | 2005-09-07 | — | — | EP | claimed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
| EP-1496982-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-10-30 | — | — | EP | disclosed |
| WO-2003088900-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003057696-A1 | DEAZAPURINES AND USES THEREOF | EISAI CO. LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-1226136-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | PIK3CD 509/4885ABL1 111/4885EGFR 147/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | PIK3CD 460/4885ABL1 324/4885EGFR 599/4885 |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | PIK3CD 509/4885ABL1 111/4885EGFR 147/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | PIK3CD 460/4885ABL1 324/4885EGFR 599/4885 |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | PIK3CD 450/4885ABL1 78/4885EGFR 11/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | PIK3CD 460/4885ABL1 324/4885EGFR 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.